Boston, MA 07\/09\/2013 (wallstreetpr) –\u00a0Response Genetics, Inc. (NASDAQ:RGDX)\u00a0is an American Pharmaceutical Company listed on NASDAQ. The stock price is currently quoted at $ 1.72, with an annual low of $ .70 and high of $ 1.89, indicating that the current market price trades near the highest price range. The total market capitalization of the company is 54.78 Million dollars. Today, the price of its equity shares has increased by 13.91 percent (+ US $ 0.21).<\/p>\n
Response Genetics, Inc. (NASDAQ:RGDX)\u00a0primarily diagnoses various cancers in human beings and focuses on getting the proper treatment. It also diagnoses the after effects of the treatment of the patients and whether the patient\u2019s response is either positive or negative.<\/p>\n
The company has recently entered into an agreement with the Blue cross and Blue Shield of Illinois, the largest health plan with 7.4 million members in Illinois, also affiliated with various agencies and associations. The oncologists and pathologists now connected with the government health plan will be able to utilize the company\u2019s testing facilities for the patients suffering from various types of cancers. Through this process, the exact medicine to be given is personalized and advised to the patient, a fact that may provide maximum relief to them. The company, based in Los Angeles, California generates its earnings from the sale and marketing of its patented diagnostic services. It has got very efficient technology for extracting and analysing information through biopsy of identified parts of the human body like tumours, liver, kidney etc.<\/p>\n
With the advent of PET scan facilities to identify and locate the existence of cancer at a specific part of the patient\u2019s body, it has become easier and much more effective to attack the cancer cells through various medicines and kill the cancerous cells without damaging the good cells of the patient\u2019s body.<\/p>\n
The future of the Company is bright as the numbers of cancer patients in the world are increasing day by day and the need for diagnostic therapy has become a necessity for humans.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 07\/09\/2013 (wallstreetpr) –\u00a0Response Genetics, Inc. (NASDAQ:RGDX)\u00a0is an American Pharmaceutical Company listed on NASDAQ. The stock price is currently quoted at $ 1.72, with […]<\/p>\n","protected":false},"author":32,"featured_media":8419,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2835,2834],"stock_ticker":[],"class_list":["post-8418","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqrgdx","tag-response-genetics-inc-nasdaqrgdx","entry"],"acf":[],"yoast_head":"\n